Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
NCT03424733 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2019-08-15
Summary
Some of the most common side effects of the multiple sclerosis drug Plegridy (pegylated interferon beta-1a) include flu-like symptoms and injection site reactions. Physicians often advise patients to take Tylenol or aspirin prior to injection, but in this study the investigators evaluated whether using a low dose of oral steroid in combination with Tylenol reduced flu-like symptoms and injection site reactions.
Conditions
Interventions
- DRUG
-
Plegridy
Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
- DRUG
-
Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
- DRUG
-
Tylenol Pill
Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Holy Name Medical Center, Inc.
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-25
- Primary Completion
- 2020-05-01
- Completion
- 2020-05-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
NCT01411514 ·Status: TERMINATED ·Phase: PHASE4
-
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
NCT00811395 ·Status: COMPLETED ·Phase: PHASE2
-
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT07207148 ·Status: RECRUITING
-
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
NCT03177083 ·Status: COMPLETED ·Phase: PHASE4
-
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
NCT02665221 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison Study of PF530 and Betaferon in Healthy Subjects
NCT02474134 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
NCT05242133 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
NCT00950248 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
NCT00418145 ·Status: TERMINATED ·Phase: PHASE3
-
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
NCT02045732 ·Status: TERMINATED ·Phase: PHASE1
-
The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
NCT01144117 ·Status: UNKNOWN ·Phase: PHASE2
-
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
NCT06677710 ·Status: SUSPENDED ·Phase: PHASE1
-
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
NCT00906399 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
NCT02228213 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574 ·Status: RECRUITING ·Phase: PHASE2
-
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
NCT00928967 ·Status: COMPLETED
-
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
NCT01332019 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Diet Study for Multiple Sclerosis
NCT02986893 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
NCT00002270 ·Status: COMPLETED ·Phase: NA
-
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2
-
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS
NCT02490943 ·Status: COMPLETED ·Phase: NA
-
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
NCT04655222 ·Status: COMPLETED
-
Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis
NCT03051646 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
NCT00913666 ·Status: COMPLETED ·Phase: PHASE4